Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

NCT00670488 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Tumors
Metastatic Solid Tumors
Cancer
Neoplasms

Interventions

DRUG: MK-2206

Sponsor

Merck Sharp & Dohme LLC